The apolipoprotein E gene ε4 allele (APOE4) is the strongest genetic risk factor for Alzheimer’s disease (AD). Over 60% of patients have at least one APOE4 allele. A drug discovery approach targeting aging and AD transcriptomic signatures suggests bumetanide might prevent or treat AD in people with the APOE4/APOE4 genotype.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
DeTure, M. A. & Dickson, D. W. Mol. Neurodegener. 14, 32 (2019).
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C. C. & Bu, G. Nat. Rev. Neurol. 15, 501–518 (2019).
Taubes, A. et al. Nat. Aging https://doi.org/10.1038/s43587-021-00122-7 (2021).
Zhao, N. et al. Neuron 106, 727–742.e6 (2020).
Tully, P. J., Hanon, O., Cosh, S. & Tzourio, C. J. Hypertens. 34, 1027–1035 (2016).
Soul, J. S. et al. Ann. Neurol. 89, 327–340 (2021).
Sprengers, J. J. et al. J. Am. Acad. Child Adolesc. Psychiatry 60, 865–876 (2021).
The authors declare no competing interests.
About this article
Cite this article
Li, Z., Zhao, N. A water pill against Alzheimer’s disease. Nat Aging 1, 868–869 (2021). https://doi.org/10.1038/s43587-021-00124-5